AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.
AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.
AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.
AHA 2018 A randomized phase 2b trial showed safety and efficacy of the antisense nucleotide AKCEA-APO(a)-Lrx at reducing Lp(a) levels in patients with CVD.
AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.
AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.
Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.
PCSK9-antibodies reduce non-cholesterol sterols but they do not significantly affect the balance between cholesterol synthesis and absorption, irrespective of cholesterol-lowering pretreatment.
The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
This is a summary of the presentation by Lars Rydén, in which he presents which patients will likely benefit from GLP-1RA therapy by discussing differences observed between GLP-1RA trials.
In the REGARDS cohort, low hs-CRP levels were associated with a reduced risk of stroke, and CHD morbidity and mortality, while low LDL-c was not associated with protective effects.